Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + docetaxel + epirubicin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), docetaxel (a taxane), epirubicin (an anthracycline), and gemcitabine (a nucleoside analog). This regimen has been studied primarily in breast cancer treatment, including high-risk early breast cancer and metastatic breast cancer. Clinical trials have examined various sequences and combinations of these agents, with some studies showing that the specific order of administration can impact both efficacy and toxicity profiles.
02
Targets
DNARNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + docetaxel + epirubicin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + docetaxel + epirubicin + gemcitabine.